Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 20458183)

1.

Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease.

Sun Y, Grabowski GA.

Autophagy. 2010 Jul;6(5):648-9. doi: 10.4161/auto.6.5.12047. Epub 2010 Jul 1.

PMID:
20458183
2.

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.

Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, Kitatani K, Hannun YA, Witte DP, Xu YH, Grabowski GA.

Hum Mol Genet. 2010 Mar 15;19(6):1088-97. doi: 10.1093/hmg/ddp580. Epub 2010 Jan 4.

3.

Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.

Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, Merrill AH Jr, Dobrenis K, Futerman AH.

Hum Mol Genet. 2014 Feb 15;23(4):843-54. doi: 10.1093/hmg/ddt468. Epub 2013 Sep 24.

4.

Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3.

Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, Brady RO.

Neurobiol Dis. 2003 Dec;14(3):595-601.

PMID:
14678774
5.

Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice.

Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, Xue L, Zhang W, Setchell KD, Witte D, Grabowski GA.

Hum Mol Genet. 2014 Aug 1;23(15):3943-57. doi: 10.1093/hmg/ddu105. Epub 2014 Mar 5.

6.

Murine models of acute neuronopathic Gaucher disease.

Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Månsson JE, Ehinger M, Richter J, Brady RO, Kirik D, Karlsson S.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17483-8. Epub 2007 Oct 22.

7.
8.

Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease.

Cabrera-Salazar MA, Bercury SD, Ziegler RJ, Marshall J, Hodges BL, Chuang WL, Pacheco J, Li L, Cheng SH, Scheule RK.

Exp Neurol. 2010 Oct;225(2):436-44. doi: 10.1016/j.expneurol.2010.07.023. Epub 2010 Jul 29.

PMID:
20673762
9.

Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease.

Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH.

Hum Mol Genet. 2011 Apr 1;20(7):1375-86. doi: 10.1093/hmg/ddr019. Epub 2011 Jan 20.

10.

Enhanced calcium release in the acute neuronopathic form of Gaucher disease.

Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, Futerman AH.

Neurobiol Dis. 2005 Feb;18(1):83-8.

PMID:
15649698
11.

Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model.

Pandey MK, Jabre NA, Xu YH, Zhang W, Setchell KD, Grabowski GA.

Mol Genet Metab. 2014 Feb;111(2):163-71. doi: 10.1016/j.ymgme.2013.09.002. Epub 2013 Sep 10.

PMID:
24079945
12.

Neuronal forms of Gaucher disease.

Vitner EB, Futerman AH.

Handb Exp Pharmacol. 2013;(216):405-19. doi: 10.1007/978-3-7091-1511-4_20. Review.

PMID:
23563668
13.

Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.

Grabowski GA, Goldblatt J, Dinur T, Kruse J, Svennerholm L, Gatt S, Desnick RJ.

Am J Med Genet. 1985 Jul;21(3):529-49.

PMID:
3927728
14.

Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies.

Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A.

Acta Neuropathol. 1984;65(2):99-109.

PMID:
6524300
15.

Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.

Xu YH, Reboulet R, Quinn B, Huelsken J, Witte D, Grabowski GA.

Mol Genet Metab. 2008 Jun;94(2):190-203. doi: 10.1016/j.ymgme.2008.01.013. Epub 2008 Mar 17.

16.

Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.

Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH.

Brain. 2012 Jun;135(Pt 6):1724-35. doi: 10.1093/brain/aws095. Epub 2012 May 7.

17.

Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Xu YH, Quinn B, Witte D, Grabowski GA.

Am J Pathol. 2003 Nov;163(5):2093-101.

18.

Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.

Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA.

Mol Genet Metab. 2011 Apr;102(4):436-47. doi: 10.1016/j.ymgme.2010.12.014. Epub 2010 Dec 31.

19.

Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.

Orvisky E, Park JK, LaMarca ME, Ginns EI, Martin BM, Tayebi N, Sidransky E.

Mol Genet Metab. 2002 Aug;76(4):262-70.

PMID:
12208131
20.

Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease.

Sanders A, Hemmelgarn H, Melrose HL, Hein L, Fuller M, Clarke LA.

Blood Cells Mol Dis. 2013 Aug;51(2):109-15. doi: 10.1016/j.bcmd.2013.03.006. Epub 2013 Apr 30.

PMID:
23642305
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk